Welcome to our dedicated page for 60 Degrees Pharm SEC filings (Ticker: SXTPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if the next malaria breakthrough is hiding in 60 Degrees Pharmaceuticals’ latest 10-K? Most biotech disclosures bury critical details—patent timelines, FDA feedback, R&D burn—in dense language. This dedicated SEC filings hub turns that maze into an accessible path.
Start with the questions investors actually ask: “Where can I find the 60 Degrees Pharmaceuticals quarterly earnings report 10-Q filing?” or “How do insider stock grants show up?” Every Form 10-Q, 10-K, 8-K and S-1 lands here the moment EDGAR posts it. Our AI-powered summaries translate clinical-stage accounting and ARAKODA sales metrics into plain English, making 60 Degrees Pharmaceuticals SEC filings explained simply a reality.
Need to monitor management moves? Receive real-time alerts for 60 Degrees Pharmaceuticals Form 4 insider transactions real-time. Compare option exercises or warrant conversions with pipeline milestones using side-by-side charts. Looking for governance insight? The most recent 60 Degrees Pharmaceuticals proxy statement executive compensation is annotated so you can spot R&D incentive structures in seconds.
Key use cases investors pursue every quarter:
- Track clinical-trial spend trends via the 60 Degrees Pharmaceuticals earnings report filing analysis
- Flag material events—FDA designations, supply-chain updates—through 60 Degrees Pharmaceuticals 8-K material events explained
- See 60 Degrees Pharmaceuticals insider trading Form 4 transactions before they hit the news
No more hunting across multiple sites—understanding 60 Degrees Pharmaceuticals SEC documents with AI means one click delivers the full story. Stay ahead with complete coverage, instant updates and expert context, whether you’re dissecting the 60 Degrees Pharmaceuticals annual report 10-K simplified or scanning the latest capital-raising S-1.
60 Degrees Pharmaceuticals, Inc. is soliciting proxies for its upcoming annual meeting to elect five directors and seek shareholder approval on several proposals. The Board recommends voting FOR the election of the five nominees, an amendment to the 2022 Equity Plan to add 250,000 shares, an amendment to the Certificate of Incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10 (to be chosen by the Board), the ratification of RBSM LLP as independent auditor for fiscal 2025, and a proposal to adjourn if additional votes are needed.
The reverse split, if approved, will combine outstanding shares automatically, eliminate fractional shares (entitling holders to whole shares instead), proportionately adjust outstanding options and warrants, and leave authorized shares at 150,000,000. The Board has not recommended votes on other potential matters; proxies may vote discretionarily on such items.
Insider option grant and ownership change at 60 Degrees Pharmaceuticals — Kristen Landon, the company’s Chief Operating Officer, was granted 4,167 stock options with an exercise price of $6.85. The options vest in five equal annual tranches beginning December 31, 2024, and have a 10-year maximum term. After the grant, Landon beneficially owns 4,167 underlying shares directly. The filing notes it was submitted late due to an administrative error and that all figures were retroactively adjusted for a 1-for-5 reverse stock split effected by the issuer.
Kristen Landon, Chief Operating Officer and director of 60 Degrees Pharmaceuticals, Inc., reports acquiring 4,540 shares of the issuer's common stock on 01/17/2025. The reported acquisition was at no cash price ($0) and leaves Ms. Landon with 4,540 shares held directly. The filing notes it was submitted late due to an inadvertent administrative error and that the reported share totals were adjusted to reflect a 1-for-5 reverse stock split effective 02/24/2025. The Form 4 is signed by the reporting person on 08/14/2025. All information is limited to this single non-derivative purchase; no derivative transactions or prices other than $0 are reported.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company marketing the FDA-approved malaria prevention product Arakoda and developing additional tafenoquine-based and other programs. For the three months ended June 30, 2025 the company reported net revenue of $257,820 (including $100,932 product revenue and $206,939 research revenue) and a gross profit of $50,881. Cash and cash equivalents were $1,966,930 at June 30, 2025, up from $1,659,353 at December 31, 2024, aided by net financing proceeds of approximately $1.7 million from January and February 2025 registered offerings.
Despite the revenue increase, the company reported a six-month net loss of $3,612,231, used $3,047,494 in operating activities during the six months, and had an accumulated deficit of $44,138,232. Derivative liabilities tied to a contingent milestone (Knight) were $776,172. Management states there is substantial doubt about the company’s ability to continue as a going concern without raising additional capital. The company also faces customer concentration (significant customers comprised ~99% of product revenue for the quarter) and sole-vendor API supply risk.
FAQ
What is the current stock price of 60 Degrees Pharm (SXTPW)?
